Prevail Therapeutics, Inc. (PRVL) relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the agreement, Prevail shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.